Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas.
hERG1 channel
ileum
neuroendocrine tumours
pancreas
prognosis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 Sep 2022
13 Sep 2022
Historique:
received:
01
08
2022
revised:
08
09
2022
accepted:
10
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
hERG1 potassium channels are widely expressed in human cancers of different origins, where they affect several key aspects of cellular behaviour. The present study was designed to evaluate the expression and clinical relevance of hERG1 protein in cancer tissues from patients suffering from neuroendocrine tumours (NETs) of ileal (iNETs) and pancreatic (pNETs) origin, with available clinicopathological history and follow-up. The study was carried out by immunohistochemistry with an anti-hERG1 monoclonal antibody. In a subset of samples, a different antibody directed against the hERG1/β1 integrin complex was also used. The analysis showed for the first time that hERG1 is expressed in human NETs originating from either the ileum or the pancreas. hERG1 turned out to have a prognostic value in NETs, showing (i) a statistically significant positive impact on OS of patients affected by ileal NETs, regardless the TNM stage; (ii) a statistically significant positive impact on OS of patients affected by aggressive (TNM stage IV) disease, either ileal or pancreatic; (iii) a trend to a negative impact on OS of patients affected by less aggressive (TNM stage I-III) disease, either ileal or pancreatic. Moreover, in order to evaluate whether ERG1 was functionally expressed in a cellular model of pNET, the INS1E rat insulinoma cell line was used, and it emerged that blocking ERG1 with a specific inhibitor of the channel (E4031) turned out in a significant reduction in cell proliferation.
Identifiants
pubmed: 36142530
pii: ijms231810623
doi: 10.3390/ijms231810623
pmc: PMC9504580
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
ERG1 Potassium Channel
0
Ether-A-Go-Go Potassium Channels
0
Integrin beta1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Association for Cancer Research
ID : 1662
Organisme : Italian Association for Cancer Research
ID : 15627
Organisme : Italian Association for Cancer Research
ID : 21510
Organisme : University of Florence
ID : N/A
Organisme : Ministry of Education, Universities and Research
ID : 20174TB8KW
Organisme : European Union
ID : 813834
Références
Br J Cancer. 2000 Dec;83(12):1722-9
pubmed: 11104572
J Theor Biol. 1986 Dec 21;123(4):377-401
pubmed: 2443763
Sci Rep. 2021 Apr 23;11(1):8847
pubmed: 33893331
Mol Cell Endocrinol. 1999 Feb 25;148(1-2):37-45
pubmed: 10221769
J Cell Biol. 2014 Jul 21;206(2):151-62
pubmed: 25049269
Transl Oncol. 2012 Apr;5(2):105-12
pubmed: 22496927
Cancers (Basel). 2019 Aug 04;11(8):
pubmed: 31382663
J Cell Biol. 1993 Sep;122(5):1131-43
pubmed: 8354696
Blood. 2007 Aug 15;110(4):1238-50
pubmed: 17420287
Protein Expr Purif. 2021 Aug;184:105879
pubmed: 33826963
Onco Targets Ther. 2016 Oct 14;9:6325-6332
pubmed: 27789963
Oncotarget. 2016 Sep 13;7(37):59535-59547
pubmed: 27517748
Neuroendocrinology. 2020;110(1-2):147-154
pubmed: 31177261
Neoplasia. 2017 Dec;19(12):991-1002
pubmed: 29091800
Br J Cancer. 2015 Mar 17;112(6):1076-87
pubmed: 25719829
Cancer Res. 2004 Jan 15;64(2):606-11
pubmed: 14744775
Am J Physiol Cell Physiol. 2022 Jun 1;322(6):C1138-C1150
pubmed: 35442831
Mol Cancer Ther. 2021 Aug;20(8):1338-1349
pubmed: 34045227
Transl Oncol. 2020 Mar;13(3):100740
pubmed: 32105990
Best Pract Res Clin Endocrinol Metab. 2016 Jan;30(1):59-77
pubmed: 26971844
Gene Expr Patterns. 2003 Dec;3(6):767-76
pubmed: 14643686
Dig Liver Dis. 2002 Sep;34(9):668-80
pubmed: 12405256
Anat Rec A Discov Mol Cell Evol Biol. 2006 Mar;288(3):304-15
pubmed: 16463373
Neuroendocrinology. 2012;95(4):317-24
pubmed: 22327359
Eur J Neurosci. 1997 Dec;9(12):2596-604
pubmed: 9517465
Head Neck. 2016 Nov;38(11):1672-1678
pubmed: 27131339
World J Gastroenterol. 2019 Oct 14;25(38):5732-5772
pubmed: 31636470
J Physiol. 2018 Mar 1;596(5):769-783
pubmed: 29333676
FASEB J. 2000 Dec;14(15):2601-10
pubmed: 11099479
Front Oncol. 2020 May 27;10:831
pubmed: 32537434
Melanoma Res. 2013 Jun;23(3):185-90
pubmed: 23524483
Mod Pathol. 2011 Apr;24 Suppl 2:S53-7
pubmed: 21455201
Cancer Res. 1998 Feb 15;58(4):815-22
pubmed: 9485040
Gastroenterology. 2008 Nov;135(5):1469-92
pubmed: 18703061
Am J Physiol Regul Integr Comp Physiol. 2008 Mar;294(3):R895-904
pubmed: 18184764
J Physiol. 1995 Dec 1;489 ( Pt 2):455-71
pubmed: 8847640
Dig Dis Sci. 2010 Apr;55(4):1004-10
pubmed: 19495974
Br J Cancer. 2005 Oct 3;93(7):781-92
pubmed: 16175187
Clin Cancer Res. 2017 Jan 1;23(1):73-80
pubmed: 27635088
Sci Signal. 2017 Apr 04;10(473):
pubmed: 28377405
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2685-702
pubmed: 25542783
Nat Rev Endocrinol. 2018 Nov;14(11):656-669
pubmed: 30158549
Am J Anat. 1974 Dec;141(4):537-61
pubmed: 4440635
J Surg Oncol. 2008 Jan 1;97(1):57-62
pubmed: 17786970
Cancer Cell Int. 2018 Jul 05;18:93
pubmed: 30002601
Eur J Surg Oncol. 2020 Jan;46(1):209-215
pubmed: 31679954
Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):1-14
pubmed: 17382262
Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):791-802
pubmed: 23582919
Biochem Biophys Res Commun. 2020 May 14;525(4):1032-1037
pubmed: 32178873
J Biol Chem. 2003 Jan 31;278(5):2947-55
pubmed: 12431979
Cancer Biol Ther. 2008 Jan;7(1):45-50
pubmed: 17938585
Cell. 1995 Apr 21;81(2):299-307
pubmed: 7736582
FASEB J. 2003 Feb;17(2):330-2
pubmed: 12490549
Clin Cancer Res. 2014 Mar 15;20(6):1502-12
pubmed: 24449824